Evidence map›Paper›PMID 35455781›Full record

ReviewHealthcare (Basel, Switzerland)2022

Disease-Specific Health Disparities: A Targeted Review Focusing on Race and Ethnicity.

Mark R Cullen, Adina R Lemeshow, Leo J Russo, David M Barnes, Yaa Ababio, Aida Habtezion

Open access · goldAbstract readReview
In one paragraph

Review in Healthcare (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
11.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. 2050: An Arthroplasty Odyssey.Healthcare (Basel, Switzerland) · 2025
    Article
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Mark R CullenIndependent Researcher, 27766 Stirrup Way, Los Altos Hills, CA 94022, USA.ORCID 0000-0001-7996-1864
Adina R LemeshowGlobal Medical Epidemiology, Worldwide Medical and Safety, Pfizer Inc., 235 E 42nd St., New York, NY 10017, USA.
Leo J RussoGlobal Medical Epidemiology, Worldwide Medical and Safety, Pfizer Inc., 235 E 42nd St., New York, NY 10017, USA.
David M BarnesGlobal Medical Epidemiology, Worldwide Medical and Safety, Pfizer Inc., 235 E 42nd St., New York, NY 10017, USA.
Yaa AbabioGlobal Medical Epidemiology, Worldwide Medical and Safety, Pfizer Inc., 235 E 42nd St., New York, NY 10017, USA.
Aida HabtezionWorldwide Medical and Safety, Pfizer Inc., 235 E 42nd St., New York, NY 10017, USA.ORCID 0000-0002-4473-006X
Pfizer (United States) · USFilm Independent · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWide disparities in health status exist in the United States across race and ethnicity, broadly driven by social determinants of health-most notably race and ethnic group differences in income, education, and occupational status. However, disparities in disease frequency or severity remain underappreciated for many individual diseases whose distribution in the population varies. Such information is not readily accessible, nor emphasized in treatment guidelines or reviews used by practitioners. Specifically, a summary on disease-specific evidence of disparities from population-based studies is lacking. Our goal was to summarize the published evidence for specific disease disparities in the United States so that this knowledge becomes more widely available "at the bedside". We hope this summary stimulates health equity research at the disease level so that these disparities can be addressed effectively.

methodsA targeted literature review of disorders in Pfizer's current pipeline was conducted. The 38 diseases included metabolic disorders, cancers, inflammatory conditions, dermatologic disorders, rare diseases, and infectious targets of vaccines under development. Online searches in Ovid and Google were performed to identify sources focused on differences in disease rates and severity between non-Hispanic Whites and Black/African Americans, and between non-Hispanic Whites and Hispanics. As a model for how this might be accomplished for all disorders, disparities in disease rates and disease severity were scored to make the results of our review most readily accessible. After primary review of each condition by one author, another undertook an independent review. Differences between reviewers were resolved through discussion.

resultsFor Black/African Americans, 29 of the 38 disorders revealed a robust excess in incidence, prevalence, or severity. After sickle cell anemia, the largest excesses in frequency were identified for multiple myeloma and hidradenitis suppurativa. For Hispanics, there was evidence of disparity in 19 diseases. Most notable were metabolic disorders, including non-alcoholic steatohepatitis (NASH).

conclusionsThis review summarized recent disease-specific evidence of disparities based on race and ethnicity across multiple diseases, to inform clinicians and health equity research. Our findings may be well known to researchers and specialists in their respective fields but may not be common knowledge to health care providers or public health and policy institutions. Our hope is that this effort spurs research into the causes of the many disease disparities that exist in the United States.

Indexed as

ethnicityhealth disparitieshealth equitypopulationracetranslationaltreatmentUnited States

Identifiers

PMID35455781
PMCPMC9025451
OpenAlexW4224322386

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.